Format

Send to

Choose Destination
See comment in PubMed Commons below
J Alzheimers Dis. 2009;16(4):731-40. doi: 10.3233/JAD-2009-1021.

Leptin: a novel therapeutic strategy for Alzheimer's disease.

Author information

1
Neurotez, Inc., Bridgewater, New Jersey 08807, USA. ntezapsidis@neurotez.com

Abstract

Adipocyte-derived leptin appears to regulate a number of features defining Alzheimer's disease (AD) at the molecular and physiological level. Leptin has been shown to reduce the amount of extracellular amyloid beta, both in cell culture and animal models, as well as to reduce tau phosphorylation in neuronal cells. Importantly, chronic administration of leptin resulted in a significant improvement in the cognitive performance of transgenic animal models. In AD, weight loss often precedes the onset of dementia and the level of circulating leptin is inversely proportional to the severity of cognitive decline. It is speculated that a deficiency in leptin levels or function may contribute to systemic and CNS abnormalities leading to disease progression. Furthermore, a leptin deficiency may aggravate insulin-controlled pathways, known to be aberrant in AD. These observations suggest that a leptin replacement therapy may be beneficial for these patients.

PMID:
19387109
PMCID:
PMC2908903
DOI:
10.3233/JAD-2009-1021
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for IOS Press Icon for PubMed Central
    Loading ...
    Support Center